| Registry | NCT02004067 |
|---|---|
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional; randomized, parallel, masking: double, treatment |
| Enrollment | 100 (Actual) |
| Sponsor | Federal University of São Paulo (Other); collaborators: Allergan |
| Conditions | Primary Sjogren Syndrome, Secondary Sjogren Syndrome, Aqueous Deficient Dry Eye Disease, Evaporative Dry Eye Disease |
| Interventions | Restasis, Refresh Endura (Drug) |
| Dates | start 2013-01-01, primary completion 2016-08-01, completion 2016-08-01, first posted 2013-12-06, last updated 2020-09-22 |
| Locations | 1 site in Brazil |
Related Papers Related Patents Related Grants Related Experts
All trials for Primary Sjogren Syndrome All trials for Secondary Sjogren Syndrome All trials of Restasis All trials of Refresh Endura
In the present study the investigators aim to determine the efficacy of an immunomodulating topical medication, compared with a topical lubricant, on the treatment of dry eye disease (DED) due to primary or secondary Sjögren's syndrome (aqueous deficient DED) and evaporative DED.
Dry eye disease (DED) is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. DED prevalence is estimated around 15 -35% of the population over 50 years old. There is a wide variety of topic medications for the treatment of DED, though few aim the re-establishment of tear osmolarity equilibrium and reduction of damages to the ocular surface. The treatment of DED can include a medical treatment, such as tear substitution, tear preservation, production stimulation, anti-inflammatory; it can also include surgical treatment, as tarsorrhaphy and salivary gland transplant. Considering tear substitutes and anti-inflammatory topical treatments, the purpose of our study is to determine efficacy of an immunomodulating topical medication containing 0.05% cyclosporine A (CsA), compared to a topical lubricant (vitamin A, Refresh Endura®), on the treatment of dry eye disease (DED) due to primary or secondary Sjögren's syndrome (aqueous deficient DED) and evaporative DED.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Refresh Endura | Active comparator | Drug: Refresh Endura | Topical lubricant containing (glycerin; polysorbate 80; castor oil; carbomer, boric acid, sodium hydroxide, purified water), one drop 2 times a day, for 3 months. |
| Restasis | Experimental | Drug: Restasis | Topical immunomodulatory lubricant (Ophthalmic emulsion containing cyclosporine 0.5 mg/mL, i.e., 0.05%), one drop 2 times a day, for 3 months |
Sex: All, ages: 18 Years to 65 Years
Inclusion Criteria: * Patients diagnosed for mild to moderate Aqueous Deficient DED (ADDED), defined as Schirmer 1 < 10mm; * Patients diagnosed for mild to moderate Evaporative DED (EDED), defined as normal Schirmer 1 and BUT < 5 seconds; * Patients submitted to refractive surgery, * Patients capable of understanding instructions, signing the term of consent and available to attend all exam visits. Exclusion Criteria: * patients with punctual occlusion, * active ocular infection or inflammatory disease, * history of herpetic keratitis, * contact lens use during trial period, * patients with glaucoma, * any eyelid globe malposition abnormality.
| Facility | City | Country | Status |
|---|---|---|---|
| Departamento de Oftalmologia da Escola Paulista de Medicina - UNIFESP | São Paulo, São Paulo | Brazil |